Active substanceCalcium folinateCalcium folinate
Similar drugsTo uncover
  • Calcium Phosphinate-Ebove®
    capsules inwards 
  • Calciumfolinate-Ebwe
    solution w / m in / in 
  • Calciumfolinate-Ebwe
    solution w / m in / in 
  • Calcium folinate-Vial
    lyophilizate w / m in / in 
    BELMEDPREPARATY, RUP     Republic of Belarus
  • Leucovorin Lahema
    lyophilizate w / m in / in 
    Pliva-Lahema, AO     Czech Republic
  • Leucovorin-LENS®
    solution w / m in / in 
    LENS-PHARM, LLC     Russia
  • Leucovorin-LENS®
    lyophilizate w / m in / in 
    LENS-PHARM, LLC     Russia
  • Leucovorin-Teva
    solution w / m in / in 
  • Dosage form: & nbsplIofilizate for solution for intravenous and intramuscular administration
    Composition:

    On one bottle:

    Active substance: calcium folinate monohydrate - 55.9 mg (in terms of folinic acid - 50.0 mg).

    Excipient: methylparahydroxybenzoate 0.50 mg.

    Description:
    PThe original mass is from light yellow to yellow in a non-uniform color. It is hygroscopic.

    Pharmacotherapeutic group:Vitamin - antidote of folic acid antagonists (modifier of biological action of fluorouracil)
    ATX: & nbsp

    V.03.A.F   Drugs that reduce the toxicity of cytostatic therapy

    Pharmacodynamics:

    Calcium folinate is a restored form of folic acid and is used as an antidote for medicines that act as antagonists of folic acid. This compound is also known as folinic acid. A folic acid antagonist, such as methotrexate, inhibits dihydrofolate reductase and, thereby, prevents the formation of tetrahydrofolate from folic acid, which serves as an important cofactor for the transfer of single-carbon residues in the biosynthesis of nucleic acids. As a result, the synthesis of nucleic acids and cell division is blocked. Calcium folinate, in contrast to folic acid, does not require the reduction of dihydrofolate reductase for conversion to tetrahydrofolate, which allows using it to restore the broken process of biosynthesis of DNA, RNA and proteins. The protective action of calcium folinata is manifested only in relation to healthy cells. Prevents the toxic effect of methotrexate on the cells of the bone marrow and gastrointestinal tract, but does not significantly affect the already provided nephrotoxic effect of methotrexate.

    Helps fill the deficiency of folic acid in the body Calcium folinate can also enhance the antitumor effect of fluorouracil. When these two drugs interact, a stable complex containing thymidylate synthetase is formed, which inhibits and suppresses the synthesis of DNA.

    The beginning of the drug: with intramuscular injection - after 10-20 minutes, with intravenous administration - less than 5 minutes. The duration of the drug, regardless of the route of administration, is 3-6 hours.

    Pharmacokinetics:

    The maximum concentration of reduced folate in the blood serum is achieved by intramuscular injection of the drug on average after 40 minutes, with intravenous administration - after 10 minutes. Penetrates through the blood-brain barrier in moderate amounts; more accumulates in the liver. Metabolized in the liver and intestinal mucosa mainly in the active metabolite 5-methyltetrahydrofolate. The half-life is 6 hours, regardless of the route of administration. It is excreted mainly by the kidneys - 80-90%, the intestines - 5-8%.

    Indications:

    - Prevention of toxic effects of methotrexate when used in high doses;

    - intoxication with folic acid antagonists (methotrexate, trimethoprim, pyrimethamine);

    - Colorectal cancer (as part of complex therapy with fluorouracil);

    - megaloblastic anemia on the background of a deficiency of folic acid (including against the background of malabsorption syndrome, malnutrition, pregnancy, sprue, in early childhood with congenital insufficiency dihydrofolate reductase).

    Contraindications:

    - Hypersensitivity to calcium folinate or any other substance included in the preparation;

    - megaloblastic anemia due to deficiency of cyanocobalamin (vitamin B12).

    Carefully:

    Alcoholism, epilepsy, chronic renal failure (CRF), children under 2 years of age (safety and efficacy for children not installed).

    Pregnancy and lactation:

    Studies of folate calcium on reproductive function in animals and humans have not been carried out. It is not known whether calcium folinate harmful effects on the fetus when prescribing the drug to pregnant women and whether it can affect reproductive function. The use of the drug during pregnancy is possible only if the intended benefit to the mother exceeds the potential risk to the fetus.

    It is not known whether the calcium folinate in breast milk, so if you need calcium folinata during lactation, you need to decide whether to stop breastfeeding.

    Dosing and Administration:

    It is administered intramuscularly or intravenously.

    When administered intravenously in one minute, no more than 160 mg of calcium folinate should be administered because of the calcium present in the solution.

    Before use with the intravenous route of administration calcium folinate can be diluted with 0.9% solution of sodium chloride or 5% solution of dextrose.

    When preparing the injection solution calcium folinate can be diluted with Ringer's solution, Ringer's solution with lactate, 10% dextrose solution, 5% dextrose solution, 0.9% sodium chloride solution to a concentration of 0.06 mg / ml to 1 mg / ml. The resulting solution remains stable for 24 hours. Discard the residue.

    Due to the fact that different schemes of calcium folinate are used, the doctor should be guided by special medical literature when choosing a specific dose.

    Prevention of toxic effects of methotrexate when used in high doses

    The following recommendations can serve as a guide for the determination of doses and the scheme of calcium folinate in adults, elderly patients (≥65 years) and children. Prevention of toxic effects of methotrexate, used in high doses,is carried out by parenteral administration in patients with malabsorption syndrome or other pathology of the digestive tract, when intestinal absorption may be difficult. Doses of 25-50 mg should be administered parenterally due to saturable absorption of calcium folinate in the intestine.

    The dose and duration of calcium folinate, first of all, depend on the scheme of therapy and doses of methotrexate, the appearance of signs of toxicity and individual features of excretion of methotrexate. Typically, the first dose of calcium folinate is 15 mg (6-12 mg / m2), the introduction begins 12-24 hours (not later than 24 hours) after the start of infusion of methotrexate. The same dose is administered every 6 hours for 72 hours. After parenteral administration of several doses of the drug, you can switch to the use of oral forms of calcium folinate.

    In addition to the introduction of calcium folinate in the prevention of toxic effects of methotrexate, used in high doses, are activities that accelerate the excretion of methotrexate (providing enhanced diuresis and alkalinization of urine). The kidney function should be monitored daily by measuring the concentration of serum creatinine.It is recommended to measure the concentration of methotrexate in the blood serum 48 hours after the start of the infusion. If the residual concentration of methotrexate is more than 0.5 μmol / l, correction of the calcium dosing regimen of folinate is necessary.

    The recommended correction of calcium folate therapy in the prevention of toxic effects of methotrexate, used in high doses, depending on its residual concentration

    The residual concentration of methotrexate in the blood after 48 hours after the onset of methotrexate

    The dose of calcium folinate, applied every 6 hours for 48 hours or until the concentration of methotrexate is lower than 0.05 μmol / l

    ≥ 0.5 μmol / l

    15 mg / m2

    ≥ 1.0 μmol / l

    100 mg / m2

    ≥ 2.0 μmol / l

    200 mg / m2

    Cytotoxic therapy in combination with fluorouracil

    Various doses and schemes of calcium folinate are used.

    Below are examples of calcium folinate administration regimens that have been used in adults and elderly patients with colorectal cancer.

    Weekly mode: calcium folinate in a dose of 20 mg / m2 administered intravenously bolus or in a dose of 200-500 mg / m2 infuzionno within 2 hours and a bolus of fluorouracil in a dose of 500 mg / m2 in the middle or at the end of calcium folinate infusion.

    Monthly mode: calcium folinate in a dose of 20 mg / m2 administered intravenously bolus or in a dose of 200-500 mg / m2 infuzionno for 2 hours, followed by bolus injection of fluorouracil at a dose of 425 mg / m2 or 370 mg / m2 for 5 consecutive days.

    Two-month mode: intravenous administration of calcium folinata in a dose of 200 mg / m2 for 2 hours, followed by bolus injection of fluorouracil at a dose of 400 mg / m2 and a 22-hour infusion of fluorouracil at a dose of 600 mg / m2 for 2 consecutive days every 2 weeks.

    The therapy should be stopped with the number of leukocytes and blood platelets of less than 3.5 thousand and 100.0 thousand, respectively. Also, therapy should be discontinued if bleeding occurs from the gastrointestinal tract, severe diarrhea (≥7 times per day), exfoliative dermatitis.

    Depending on the patient's condition, clinical response and manifestations of toxicity of therapy, fluorouracil dose adjustment may be required (see the instructions for using fluorouracil). A decrease in the dose of calcium folinate is not required.

    The number of repeated cycles is at the discretion of the attending physician.

    Intoxication with folic acid antagonists (methotrexate, trimethoprim, pyrimethamine)

    Methotrexate overdose

    In case of an accidental overdose of methotrexate, the drug is administered at a dose equal to or greater than the dose of methotrexate administered no later than 1 hour after methotrexate injection, then the drug is injected every 3 hours at 10 mg / m2 until the disappearance of signs of toxicity.

    Toxicity of trimethoprim

    After stopping the administration of trimethoprim, calcium folinate in a dose of 3-10 mg / day until the recovery of the parameters of a clinical blood test.

    The toxicity of pyrimethamine

    In the case of high doses of pyrimethamine or a prolonged period of treatment with low doses, calcium folinate in a dose of 5-50 mg / day, depending on the parameters of a clinical blood test.

    In the treatment of megaloblastic anemia, caused by a deficiency of folic acid, the drug is used in a dose of 5 mg (maximum to 15 mg) per day.

    Side effects:

    Side effects are listed below for organs and systems with the frequency of their occurrence: Often (> 10%), often (from> 1% and <10%), infrequently (> 0.1% and <1%), rarely (> 0.01% and <0.1%), rarely (< 0,01%), frequency is unknown - by data to establish the frequency of occurrence is not possible.

    Immune system disorders: rarely - anaphylactoid / anaphylactic reactions (including anaphylactic shock), allergic reactions and urticaria.

    Disorders of the psyche: rarely - insomnia, anxiety and depression after applying high doses.

    Disturbances from the nervous system: rarely - increased incidence of epileptic seizures.

    Disorders from the gastrointestinal tract: rarely - nausea, dyspepsia (when applying high doses).

    General disorders: infrequently, fever.

    Stevens-Johnson syndrome and toxic epidermal necrolysis, including fatal cases, have been reported in patients taking calcium folinate in combination with other drugs (for which the occurrence of these complications are described). It is impossible to exclude the contribution of calcium folinate to the development of Stevens-Johnson syndrome and toxic epidermal necrolysis.

    Additional side effects when used in combination with fluorouracil

    Disorders from the gastrointestinal tract: very often - nausea, vomiting, diarrhea and severe dehydration, requiring hospitalization (can lead to death).

    Disturbances from the liver and bile ducts: frequency unknown - hyperammonia.

    Disturbances from the skin and subcutaneous tissues: frequency is unknown - palmar dandruff erythrodysesthesia.

    General disorders: very often - inflammation of the mucous membrane, including stomatitis, cheilitis, pharyngitis, esophagitis, proctitis.

    Overdose:

    The effect of a much higher than recommended dose of calcium folinate was not reported. However, high doses of calcium folinate can neutralize the chemotherapeutic effect of folic acid antagonists.

    In case of an overdose with a combination of fluorouracil with calcium folinate, it is necessary to carry out the measures described in the instructions on application fluorouracil.
    Interaction:

    - Reduces the effectiveness of folic acid antagonists (eg, cotrimoxazole, pyrimethamine).

    - Reduces anticonvulsant activity of phenobarbital, phenytoin and primidone.

    - May lead to an increase in both the therapeutic and toxic effects of fluorouracil, and therefore, when combined, fluorouracil doses should be reduced.

    - There are reports of incompatibility of injection forms of calcium folinate with simultaneous application with injection forms of droperidol, fluorouracil,foscarnet sodium and methotrexate due to the formation of precipitate or turbidity of injectable solutions.

    Special instructions:

    Calcium folinate should be administered intramuscularly or intravenously.

    You can not enter it intrathecally, because possible fatal outcome.

    Treatment with calcium folinate in combination with methotrexate or fluorouracil should only be done under the supervision of a doctor who has experience with antitumor drugs.

    The use of calcium folinate in pernicious and other megaloblastic anemias, caused by a deficiency of cyanocobalamin (a vitamin AT12), can lead to hematological remission with simultaneous progression of neurological disorders.

    Many cytotoxic drugs cause the development of macrocytosis (in particular, direct and indirect inhibitors of DNA synthesis - hydroxycarbamide, cytarabine, mercaptopurine, thioguanine). This macrocytosis does not require the treatment of calcium folinate.

    In patients with epilepsy receiving treatment with phenobarbital, primidon, phenytoin, concurrent use of calcium folinate can increase the frequency of epileptic seizures due to a decrease in plasma concentrations of antiepileptic drugs.Clinical monitoring, control of the concentration of drugs in the blood plasma and, if necessary, correction of the dose of antiepileptic drugs during and after the termination of calcium folate therapy is recommended.

    Calcium folinate / fluorouracil

    Calcium folinate enhances the toxic effect of fluorouracil, and the risk of developing toxic effects increases, especially in elderly and debilitated patients. Dozolimitiruyuschimi side effects are leukopenia, mucositis, stomatitis and diarrhea.

    When fluorouracil is used in combination with calcium folinate, in case of toxic effects, fluorouracil doses should be reduced more significantly than with monotherapy. If the patient has signs of toxic damage to the gastrointestinal tract (eg, mucositis, stomatitis, diarrhea), regardless of the severity of the lesion, do not start or continue combined therapy with fluorouracil and calcium folinate until they are completely resolved.

    Since diarrhea can be a toxic effect on the gastrointestinal tract, patients with this side effect should be carefully monitored until it disappears completely.This is necessary because of the possible rapid deterioration of the clinical picture, leading to death. If diarrhea and / or stomatitis occurs in the treatment of a patient, it is recommended that the dose of fluorouracil be reduced to their full extinction, especially in elderly and weakened patients. In elderly patients and patients who underwent previous radiation therapy, it is recommended to begin therapy with reduced doses of fluorouracil.

    Calcium folinate can not be mixed with fluorouracil with simultaneous intravenous administration.

    In patients receiving combined fluorouracil / calcium folinate therapy, the concentration of calcium ions in the blood plasma should be monitored. When determining low concentrations, it is necessary to administer the appropriate calcium preparations.

    Calcium folinate / methotrexate

    Calcium folinate does not protect against non-hematologic toxic effects during methotrexate therapy (for example, from nephrotoxic effects due to precipitation of methotrexate or its metabolites in the renal tubules). The presence of a previous or methotrexate-induced renal failure,which is associated with delayed excretion of methotrexate, may require the use of higher doses or longer duration of calcium folate therapy.

    High doses of calcium folinate should be avoided, as this may lead to a decrease in the antitumor activity of methotrexate, especially in tumors of the central nervous system, when calcium folinate accumulation occurs after several courses of treatment.

    In case of development of resistance to methotrexate due to worseThe functioning of membrane transport also develops resistance to calcium folate, since both substances are transported by the same transport system.

    In case of accidental overdose with a folic acid antagonist, such as methotrexate, it is necessary to provide emergency medical care, since an increase in the time interval between the administration of methotrexate and calcium folinate leads to a decrease in the effectiveness of the latter.

    In the event of clinical manifestations of toxicity or deviations in laboratory tests, the likelihood of the patient using other drugs should always be considered,which interact with methotrexate (eg, drugs that can affect the elimination of methotrexate or bind to blood plasma proteins).

    When working with calcium folinate, it is necessary to observe the rules for handling cytotoxic substances. It is recommended to treat the contaminated surface with a dilute solution of sodium hypochlorite (containing 1% chlorine). If the product gets on the skin, immediately flush the skin with soap and water or a solution of sodium bicarbonate; In case of contact with eyes, remove eyelids and rinse eyes (eyes) with plenty of water for 15 minutes.

    Effect on the ability to drive transp. cf. and fur:

    The drug does not affect the ability to drive vehicles and engage in other potentially hazardous activities requiring increased concentration of attention and speed of psychomotor reactions, taking into account the profile of side effects.

    Form release / dosage:

    Lyophilizate for the preparation of solution for intravenous and intramuscular injection, 50 mg.

    Packaging:

    By 50 mg in terms of folinic acid in bottles of clear glass,Stoppered with rubber stoppers and cured with aluminum or combined or aluminum-plastic or aluminum caps with a plastic cover.

    One or five vials together with the instruction for use are placed in a pack of cardboard.

    Packing for hospitals: 40 vials with equal amounts instructions for use in group boxes.

    Storage conditions:

    Store in a dark place at a temperature of no higher than 25 ° C.

    Keep out of the reach of children.

    Shelf life:

    2 years.

    Do not use after the expiration date.

    Terms of leave from pharmacies:On prescription
    Registration number:LP-003462
    Date of registration:16.02.2016
    Expiration Date:16.02.2021
    The owner of the registration certificate:BELMEDPREPARATY, RUP BELMEDPREPARATY, RUP Republic of Belarus
    Manufacturer: & nbsp
    BELMEDPREPARATY, RUP Republic of Belarus
    Representation: & nbsp"Belmedpreparaty" RUP "Belmedpreparaty" RUP
    Information update date: & nbsp23.11.2017
    Illustrated instructions
      Instructions
      Up